Eric Boodman, a STAT general assignment reporter, is the author of a series about sickle cell disease and forced sterilizations. She knew what it was to have pain she couldn’t put into words ...

Staff lined the hallway, cheering and waving noisemakers. He had just become the first patient to receive a gene therapy for sickle cell since it was approved — a therapy that is expected to ...

Pfizer PFE0.78%increase; green up pointing triangle said it is voluntarily withdrawing all lots of its sickle-cell drug Oxbryta in all markets where it is approved, two years after acquiring its ...

Titled "Building with Living Trees", this first instalment highlights the stories behind Casa Jardín (Garden House), a single-family home located in the suburban area of Quito, Ecuador.

A couple of months ago, I sat with the founder of the Disability and Sickle Cell Organisation of Nigeria, Mr Tayo Faloye, for an interview that has since been published online. Tayo himself is a ...

Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much urgency to start on these expensive therapies, said Kevin Niehoff ...

LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what ...

But not everyone has the space for a large outdoor garden. If you live in an apartment or lack usable yard space, you can still create your dream garden indoors -- just start with plant pods.

Life will never be the same for Leila and Errol after the death of their 22-year-old son Darnell, who lived with disabilities including sickle cell disease. Darnell Smith died on 23 November 2022 ...

Our mission is to deliver unbiased, fact-based reporting that holds power to account and exposes the truth. Whether $5 or $50, every contribution counts. Support us to deliver journalism without ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

(NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.